ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results And Provides Corporate Update
Published: Jan 31, 2014
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended December 31, 2013 – the second quarter of the Company’s 2014 fiscal year. ImmunoGen also provided an update on Company and partner product programs.
Help employers find you! Check out all the jobs and post your resume.